News | March 06, 2009

Siemens Adds 16-Slice Biograph TruePoint PET/CT System

March 6, 2008 – Siemens expands is imaging portfolio with the addition of the Biograph TruePoint 16-slice PET/CT imager, a Works in Progress (WIP) pending 510k approval, in order to offer affordable access to high-quality imaging.

The Biograph TruePoint PET/CT imaging family includes High-Definition PET/CT and now expands its offering with 16-slice CT capabilities. The Biograph TruePoint 16-slice PET/CT will be highlighted this week at the European Congress of Radiology, March 6-10, in Vienna, Austria.

”The introduction of this particular system is critical as we continue to search for the balance between innovation and access. The likelihood that universal adoption of PET/CT technology will increase with accessibility is a shared industry vision. As an industry leader, it is our responsibility to make that vision more readily attainable,” said Michael Reitermann, CEO, Molecular Imaging, Siemens Healthcare. “The Biograph TruePoint 16-slice PET•CT is a means to achieve that end, with high performance technology housed in an economical package.”

As the U.S. and international economies struggle to increase the quality of patient care and, simultaneously, reduce healthcare costs, Biograph TruePoint 16-slice PET/CT represents a viable solution for healthcare providers. Offering an affordable and reliable imaging system with high-performance capabilities, the 16-slice Biograph PET/CT offers features, such as High-Definition PET and routine 10-minute, whole-body imaging.

The system is built for patient comfort and reflects features of the Siemens flagship Biograph mCT model. It is equipped with a 500-pound (227 kg) capacity patient bed and efficient workflow system. The system offers faster scan speeds at lower patient doses; important when patients need multiple scans for oncology treatment planning and follow-up.

The complete Biograph family of PET/CT imagers now offers options in TruePoint PET/CT for 6-, 16-, 40- and 64-slice CT configurations, as well as the Biograph mCT technology platform with 40-, 64- and 128-CT slice capabilities. The expanding Biograph family of imagers continues to be a comprehensive portfolio of solutions with upgrade possibilities and non-obsolescence protection. The new Biograph 16-slice PET/CT system is also mobile-ready, equipped to maximize on-location patient throughput with fast, 10-minute imaging.

The Biograph 16-slice PET/CT offers 2 mm uniform PET resolution throughout the field of view and a two-time improvement in signal-to-noise ratio, which provides for small lesion detection. Fast scanning and low patient radiation dose is accomplished through Siemens TrueV extended PET field of view. Providers can achieve scans at twice the scan speed or half the patient dose.

Siemens’ industry-leading dose protection, Care Dose 4D, is also included with Biograph TruePoint systems. With advanced imaging tools, the Biograph 16-slice PET•CT system offers an affordable and reliable imaging solution that can satisfy the needs of an institution of any size, and is able to grow at the same rate as clinical requirements dictate.

*This product is a Works in Progress (WIP) pending 510k approval and is not yet commercially available in the U.S. This product does not yet fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations. It is not yet commercially available in the European Union.

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

News | PET-CT | June 09, 2017
Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Overlay Init